Summit Therapeutics (SMMT) Non-Current Deferred Tax Liability (2017 - 2020)

Summit Therapeutics (SMMT) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $2.1 million in Q3 2020.

• Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $2.1 million in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $2.1 million (changed N/A YoY) and the FY2019 annual result came in at $2.1 million, changed N/A from the prior year.
• Non-Current Deferred Tax Liability declined to $2.1 million in Q3 2020, from $2.2 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.3 million in Q2 2018 to a low of $701273.5 in Q1 2017.
• A 4-year average of $2.2 million and a median of $2.1 million in 2019 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2018 — Non-Current Deferred Tax Liability jumped 357.18% — and 2019, when it plunged 33.03%.
• Tracing SMMT's Non-Current Deferred Tax Liability over 4 years: stood at $701273.5 in 2017, then jumped by 215.9% to $2.2 million in 2018, then retreated by 9.46% to $2.0 million in 2019, then advanced by 5.1% to $2.1 million in 2020.
• The last three Non-Current Deferred Tax Liability figures came in at $2.1 million (Q3 2020), $2.2 million (Q1 2020), and $2.0 million (Q4 2019), per Business Quant data.